Futura Medical plc
("Futura" or the "Company")
Remuneration of Non-Executive Directors and Total Voting Rights
17 January 2024
Futura Medical plc (AIM: FUM) (the "Company"), the pharmaceutical company developing innovative sexual health products, announces the issue of 43,500 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2023 remuneration of its Non-Executive Directors.
Remuneration of Non-Executive Directors
In accordance with the terms of their service agreements, the Non-Executive Directors receive 25 per cent of their remuneration in the form of Ordinary Shares which are usually in January following the period end. For 2023, these were issued at 51.50 pence per share, being the average closing mid-market price of the last 10 trading days of 2022 (as announced via RNS on 12 January 2023).
The 43,500 new Ordinary Shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued to the following Non-Executive Directors:
| Director | Number of Ordinary Shares issued for 2023 remuneration | Total number of ordinary shares held | Percentage of the Company's resulting issued share capital |
| Jeff Needham | 11,617 | 27,961 | 0.01% |
| Andrew Unitt | 11,970 | 38,496 | 0.01%
|
In addition, 19,913 shares have been issued to John Clarke. John Clarke was a Non-Executive Director until July 2023 and these shares represent 25 per cent of his pro-rata remuneration for the period January to July 2023 in accordance with his service agreement.
The shares element of the Non-Executive Directors' remuneration for 2024 will be awarded at 27.10 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2023. The Non-Executive Directors will receive these shares in January 2025.
Total Voting Rights
Application has been made to the London Stock Exchange and it is anticipated that trading of the new Ordinary Shares will commence on AIM at 8:00am on 22 January 2024.
Immediately following the above issue, the Company will have 301,449,451 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 301,449,541 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.Futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker /Benjamin Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.
MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.
MED3000 is being manufactured and commercialised under the brand name Eroxon® and has been granted marketing authorisation by the FDA in the US, CE marked in Europe, UKCA marked in the UK and is gaining regulatory approval in a growing number of countries across the world. Futura has commercial agreements with Haleon for the US market and Cooper Consumer Health for Europe.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a)
| Name
| Jeff Needham | ||||
| 2 | Reason for the notification | |||||
| a)
| Position/status
| Director/ PDMR | ||||
| b)
| Initial notification /Amendment
| Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name
| Futura Medical plc | ||||
| b)
| LEI
| 21380053QLT46UNV2303 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 0.2p each
GB0033278473 | ||||
| b)
| Nature of the transaction
| Issue of shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
| e)
| Date of the transaction
| 16 January 2024 | ||||
| f)
| Place of the transaction
| Outside of trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a)
| Name
| Andrew Unitt | ||||
| 2 | Reason for the notification | |||||
| a)
| Position/status
| Director/ PDMR | ||||
| b)
| Initial notification /Amendment
| Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name
| Futura Medical plc | ||||
| b)
| LEI
| 21380053QLT46UNV2303 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 0.2p each
GB0033278473 | ||||
| b)
| Nature of the transaction
| Issue of shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
|
Not applicable
| ||||
| e)
| Date of the transaction
| 16 January 2024 | ||||
| f)
| Place of the transaction
| Outside of trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
